Diamond-Blackfan anemia overview: Difference between revisions
| Line 133: | Line 133: | ||
===Surgery=== | ===Surgery=== | ||
Corrective surgery can be performed for the correction of congenital abnormalities. | |||
===Primary Prevention=== | ===Primary Prevention=== | ||
Revision as of 00:19, 8 August 2020
|
Diamond-Blackfan anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diamond-Blackfan anemia overview On the Web |
|
American Roentgen Ray Society Images of Diamond-Blackfan anemia overview |
|
Risk calculators and risk factors for Diamond-Blackfan anemia overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Diamond-Blackfan anemia (DBA) is a congenital erythroid aplasia that usually presents in infancy.The classic form is characterized by a profound normochromic and usually macrocytic anemia with normal leukocytes and platelets. About half of the affected patients have congenital malformations, and growth retardation in 30% of affected individuals. The symptoms and physical findings associated with DBA vary greatly from person to person.The hematologic complications occur in 90% of affected individuals during the first year of life.[1]
Historical Perspective
Diamond and Blackfan described congenital hypoplastic anemia in 1938. In 1951, responsiveness to corticosteroids was reported. In 1961, Diamond and colleagues presented longitudinal data on 30 patients and noted an association with skeletal abnormalities. In 1997 a region on chromosome 19 was determined to carry a gene mutated in DBA. In 1999, mutations in the ribosomal protein S19 gene (RPS19) were found to be associated with disease in some of the patients. In 2001, it was determined that a second DBA gene lies in a region of chromosome 8. In 2007, Furthermore, mutations in large ribosomal subunit-associated proteins rpl5, rpl11, and rpl35a, have been described. In 2010, 10 additional DBA genes are identified. Non-RP gene, GATA1, was identified in 2012. The largest study to date, provides a genetic explanation for nearly 80 percent of patients. Researchers still want to know why steroids often work in DBA, find more mutations, and address some questions about Diamond-Blackfan anemia.
Classification
Based on diagnostic criteria established by an International Consensus Conference.1 A diagnosis of classical DBA is made in the presence of all the diagnostic criteria and a diagnosis of non-classical DBA in the presence of i) 3 diagnostic criteria and one major supporting criterion or 2 minor criteria; ii) 2 diagnostic criteria and 3 minor supporting criteria; iii) 2 major supporting criteria, even in the absence of diagnostic criteria.
Pathophysiology
DBA has revealed itself as a "Ribosomapathy. Mutations in ribosomal protein genes have been confirmed to be the direct cause of faulty erythropoiesis and anemia.DBA mutations reduce the actual numbers of ribosomes in blood precursor cells. Without enough ribosomes, the precursors can’t produce enough GATA1, so mature red cells never form. Other blood cells — like platelets, T cells, and B cells — are not affected since they’re not dependent on GATA1. Based on a documented pathogenetic hypothesis which has been named " ribosomal stress ", ultimately a defective ribosome biosynthesis leads to apoptosis in those defective erythroid progenitors which in turn is leading to erythroid failure. In ‘‘ribosomal stress, reduced RP synthesis activates p53 that induces the downstream events and leads to cell cycle termination or apoptosis, leading to erythroid failure.
Causes
About 80%-85% of the affected patients have been found to have a heterozygous mutation in a gene encoding a small (RPS7, RPS10, RPS15A, RPS17, RPS19, RPS20, RPS24, RPS26, RPS27 RPS28, RPS29) or large (RPL5, RPL11, RPL15, RPL17, RPL19, RPL26, RPL27, RPL31 RPL35A) ribosomal subunit-associated protein. In the remaining 10-15% of DBA cases, no abnormal genes have yet been identified. It is likely that mutations are in a regulatory region including intronic regions and promoters in one of the known RP genes and may account for the DBA phenotype.
Differentiating Diamond Black-fan Anemia from Other Diseases
Diamond Black-fan Anemia must be differentiated from other diseases that cause Anemia and bone marrow failure such as Aplastic anemia, Fanconi anemia, Transient Erythroblastopenia of Childhood, Shwachman-Diamond syndrome, Pearson syndrome, Dyskeratosis congenita, Cartilage-hair hypoplasia, Congenital amegakaryocytic thrombocytopenia, Infections: Parvovirus B19, HIV, Viral hepatitis, Drugs, and toxins (eg. antileptic drugs, azathioprine), Immune-mediated disorders( eg Thymoma, Myasthenia Gravis, SLE)
Epidemiology and Demographics
Incidence of Classical Diamond-Blackfan anemia (DBA) is about seven per million live births per year. Thus in the United States, with 4 million live births per year, each year approximately 25-35 new patients will be diagnosed. The prevalence of DBA is approximately 5000 cases worldwide.DBA is usually first diagnosed in infancy. The average age of presenting with anemia is two months and the average age of diagnosis with DBA is 3-4 months. There is no racial predilection to DBA. DBA affects men and women equally.
Risk Factors
Common risk factors in the development of DBA include positive family history, having a known genetic cause.
Screening
There is no routine screening.
Natural History, Complications, and Prognosis
DBA typically present with common symptoms of anemia, including pale skin, sleepiness, irritability, tachycardia. Common complications of DBA include physical abnormalities, Cancer predisposition, eye problems such as cataracts, glaucoma, or strabismus, kidney abnormalities, hypospadias, and secondary complications due to standard therapies( Corticosteroids treatment, Red cell transfusion, Bone marrow transplantation). Prognosis is relatively good, Overall actuarial survival is 75% at age 40 years
Diagnosis
Diagnostic Study of Choice
- Diagnosing DBA is usually hard due to its partial phenotypes and the wide inconsistency of clinical expressions. the International Clinical Consensus Conference stated diagnostic and supporting criteria for the diagnosis of DBA.
- Diagnostic criteria
- Normochromic, often macrocytic anemia developing in the first year of life
- Profound reticulocytopenia
- Normocellular bone marrow with selective deficiency of erythroid precursors
- Normal or slightly reduced leukocyte count
- Normal or slightly increased platelet count
- Major supporting criteria
- Gene mutation described in ‘‘classical’’ DBA
- Positive family history
- Minor supporting criteria
- Elevated erythrocyte adenosine deaminase activity
- Congenital anomalies described in ‘‘classical’’ DBA
- Elevated HbF
- No evidence of another inherited bone marrow failure syndrome
| Classical DBA
All diagnostic criteria are met
3 Diagnostic criteria + positive family history OR 2 Diagnostic criteria + 3 minor criteria OR 3 Minor criteria + positive family history
DBA associated gene mutation without sufficient diagnostic criteria |
History and Symptoms
Classic DBA: Symptoms of anemia include fatigue, weakness, and an abnormally pale appearance (pallor). The symptomatic onset of Diamond black-fan anemia becomes apparent during the first year of life. Approximately half of DBA cases have Congenital malformations, in particular craniofacial, upper-limb, heart, and genitourinary malformations. Non-classic DBA: presents with mild or absent anemia with only subtle indications of erythroid abnormalities such as macrocytosis, elevated ADA, and/or elevated HbF concentration Have mild anemia beginning later in childhood or in adulthood, while others have some of the physical features but no bone marrow problems. Minimal or no evidence of congenital anomalies or short stature.
Physical Examination
Common physical examination findings of DBA include signs of anemia such as pallor, tachycardia, and congenital abnormalities, in particular craniofacial, upper-limb, heart, and genitourinary malformations.
Laboratory Findings
A diagnosis of DBA is made on the basis of anemia, low reticulocyte (immature red blood cells) counts, and diminished erythroid precursors in the bone marrow. Blood tests, genetic tests, and bone marrow aspiration could help in the diagnosis of DBA.
Electrocardiogram
It can use for the diagnosis of congenital heart abnormalities or complications of iron overloads in transfusion red cell-dependent patients such as arrhythmia.
X-ray
It can use for the diagnosis of congenital physical abnormalities.
Echocardiography and Ultrasound
Renal ultrasound and echocardiography should be done to diagnosis any renal or cardiac abnormalities.
CT scan
It can use for the diagnosis of congenital physical abnormalities.
MRI
It can use for the diagnosis of congenital physical abnormalities.
Other Imaging Findings
There are no other imaging findings associated with DBA.
Other Diagnostic Studies
Additional blood tests or genetic tests such as exome sequencing, genome sequencing, and mitochondrial sequencing may be ordered to rule out other types of anemia or other disorders.
Treatment
Medical Therapy
Treatment options:
- Corticosteroids therapy
- Red blood cell transfusion
- Stem cell transplantations
- Chelation therapy in iron overload
- Cancer treatment
Interventions
- Hematopoietic stem cell transplant (HSCT) is the sole curative option, but carries significant morbidity and is generally restricted to those with a matched related donor.
- Ultimately, 40% of case subjects remain dependent upon corticosteroids which increase the risk of heart disease, osteoporosis, and severe infections.
- Another 40% become dependent upon red cell transfusions which require regular chelation to prevent iron overload and increases the risk of alloimmunization and transfusion reactions, and can cause severe co-morbidities.
Surgery
Corrective surgery can be performed for the correction of congenital abnormalities.
Primary Prevention
Secondary Prevention
Prevention of secondary complications
- Iron chelation
- usually started after ten to 12 transfusions (170-200 mL/kg of packed red blood cells), when serum ferritin concentration reaches 1,000-1,500 µg/L, or when the hepatic iron concentration reaches 6-7 mg/g of dry weight liver tissue
- Deferasirox is recommended in individuals age two years or older.
- Desferrioxamine
- usually started after ten to 12 transfusions (170-200 mL/kg of packed red blood cells), when serum ferritin concentration reaches 1,000-1,500 µg/L, or when the hepatic iron concentration reaches 6-7 mg/g of dry weight liver tissue
- Corticosteroids side effects:
- One of the critical side effects of corticosteroids is growth retardation. If growth is severely impaired, corticosteroids should be stopped.[2]
References
- ↑ Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean L, Stephens K, Amemiya A. PMID 20301295. Vancouver style error: initials (help); Missing or empty
|title=(help) - ↑ Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean L, Stephens K, Amemiya A, Clinton C, Gazda HT. PMID 20301769. Vancouver style error: initials (help); Missing or empty
|title=(help)